Dr. Lambert is a regular researcher at the CHU de Québec-Université Laval Research Center and an assistant professor at the Faculty of Medicine of l’Université Laval in the department of Molecular Medicine. Dr. Lambert’s work aims to decipher how epigenetic regulators are assembled into functional units at the level of chromatin and how they impact transcription in healthy and cancerous cells. To address these fundamental questions, Dr. Lambert employs a multidisciplinary approach that includes mass spectrometry-based proteomics, protein biochemistry and cancer biology. He was recently awarded a prestigious Scholarship for the Next Generation of Scientists from the Cancer Research Society to support him as he establishes his research program.

Characterization of bromodomain-containing proteins in hormone-responsive cancers

Bromodomain-containing proteins are epigenetic regulators involved in many facets of the transcription process. Recently, numerous bromodomain inhibitors have been developed enabling the modulation of their activity for therapeutic benefit. Dr. Lambert’s group is currently investigating the functions of bromodomain-containing proteins in the context of hormone-responsive breast cancers to define their physical interplay with hormone receptors. In addition, Dr. Lambert is defining how specific cancer contexts impinged on bromodomain-containing proteins function and whether they generate actionable vulnerabilities that can targeted with bromodomain inhibitors.

Development of innovative functional proteomics technologies

To enable functional studies of epigenetic regulators, Dr. Lambert’s group is developing and implementing novel proteomics technologies to enable the study of proteomes, protein-protein interactions and post-translational modifications from clinically relevant samples. A particular focus of Dr. Lambert’s efforts remains the study of protein complexes associated with chromatin allowing the elucidation of the mechanisms enabling the ordered recruitment of epigenetic regulators to particular genomic loci.

CHUL
2705, boulevard Laurier
R-4779
Québec, QC
Canada G1V 4G2
82 entries « 9 of 9 »

Lambert JP, Mullett WM, Kwong E, Lubda D

Stir bar sorptive extraction based on restricted access material for the direct extraction of caffeine and metabolites in biological fluids

Journal Article

J Chromatogr A, 1075 (1-2), 2005.

Abstract | Links:

Lambert JP, Ethier M, Smith JC, Figeys D

Proteomics: from gel based to gel free

Journal Article

Anal Chem, 77 (12), 2005.

| Links:

82 entries « 9 of 9 »
Signaler des ajouts ou des modifications

Active projects

  • Characterization of the scaffolding roles of bromodomain containing proteins at the level of chromatin, from 2017-04-01 to 2024-03-31
  • Covid-19 effects on ARTErial StIffness and vascular AgiNg (CARTESIAN) study- Canada, from 2021-06-01 to 2024-05-31
  • Elucidation of bromodomain functions within SWI/SNF complexes, from 2020-04-01 to 2025-03-31
  • Étude des interactions bromodomain-dépendantes et de leurs impacts sur le cycle de transcription, from 2022-07-01 to 2026-06-30
  • Mitochondria bound to lipid droplets as new regulators of insulin resistance, from 2022-12-01 to 2025-11-30
  • Structural characterization of full-length BET proteins and their functional implications to cancer, from 2022-09-01 to 2024-08-31
  • TBC1D9: therapeutic target of the aggressiveness of triple negative breast cancer, from 2023-03-01 to 2024-02-29
  • Tetrahymena thermophila - un model évolutionnaire divergent pour découvrir de nouveau modes de régulation transcriptionnelle, from 2022-03-15 to 2025-03-14

Recently finished projects

  • Caractérisation du protéome mitochondrial de la prostate, from 2022-09-21 to 2023-03-31
  • Caractérisation fonctionnelle des régulateurs épigénétiques et de leurs rôles dans des modèles de cancer, from 2018-07-01 to 2022-06-30
  • Caractérisation fonctionnelle des régulateurs épigénétiques et de leurs rôles dans des modèles de cancer, from 2018-07-01 to 2022-06-30
  • COVID19 persistent symptomatology: an investigation of the metabolomic and proteomic underpinning, from 2021-06-01 to 2022-05-31
  • Investigating TBC1D9 therapeutic potential for triple negative breast cancer, from 2022-09-21 to 2023-03-31
  • Predict to prevent: Advanced proteomics profiling for precision medicine, from 2021-03-23 to 2022-09-30
  • Using BET bromodomain inhibitors to create phenotypic lethality in melanoma, from 2020-09-01 to 2022-08-31
Data provided by the Université Laval research projects registery